中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (6): 403-407.doi: 10.12144/zgmfskin202606403

• 论著 • 上一篇    下一篇

长脉冲1064 nm Nd:YAG激光联合2%盐酸卡替洛尔滴眼液外用治疗婴幼儿血管瘤疗效评价

孙丽娜1,张静杰1,袁相凤1,庞云燕1,刘国艳2，3   

  1. 1山东第二医科大学附属医院皮肤科，山东潍坊，261000；2山东第一医科大学附属皮肤病医院，山东济南，250022；3山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2026-06-15 发布日期:2026-06-04

Efficacy of long-pulse 1064 nm Nd:YAG laser combined with topical 2% carteolol hydrochloride ophthalmic solution in the treatment of infantile hemangioma

SUN Lina1, ZHANG Jingjie1, YUAN Xiangfeng1, PANG Yunyan1, LIU Guoyan2,3   

  1. 1 Affiliated Hospital of Shandong Second Medical University, Weifang 261000, China; 2 Dermatology Hospital of Shandong First Medical University, Jinan 250022, China; 3 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2026-06-15 Published:2026-06-04

PDF (PC)

4

摘要： 目的：评价长脉冲1064 nm Nd:YAG激光联合2%盐酸卡替洛尔滴眼液外用治疗中低风险浅表性增殖期婴幼儿血管瘤（IH）的临床疗效与安全性。方法：回顾性分析山东第二医科大学附属医院皮肤科收治的98例中低风险浅表性增殖期IH患儿资料，根据治疗方案分为激光组（单用长脉冲1064 nm Nd:YAG激光，48例）与联合组（长脉冲1064 nm Nd:YAG激光联合2%盐酸卡替洛尔滴眼液外用，50例）。比较两组的有效率、显效率、激光治疗次数及不良反应发生率。计数资料组间比较采用χ2检验或Fisher精确概率法。结果：联合组的有效率、显效率（90.0%、76.0%）高于激光组（83.3%、58.3%），差异均具有统计学意义（均P＜0.05）；联合组激光治疗次数为(2.63±0.97)次，显著少于激光组(4.25±1.07)次，差异具有统计学意义（P＜0.01）; 联合组不良反应发生率（12%）显著低于激光组（29%），差异具有统计学意义（P＜0.001）。结论：2%盐酸卡替洛尔滴眼液外用可增强长脉冲1064 nm Nd:YAG激光治疗中低风险浅表性增殖期IH的疗效，减少激光治疗次数及不良反应发生。

关键词: 婴幼儿血管瘤, β受体阻滞剂, 2%盐酸卡替洛尔滴眼液, 长脉冲1064 nm Nd:YAG激光

Abstract: Objective: To assess the efficacy and safety of longpulse 1064 nm Nd:YAG laser combined with topical 2% carteolol hydrochloride ophthalmic solution in the treatment of lowtomoderate risk superficial proliferative infantile hemangiomas (IH). Methods: A retrospective analysis was performed on 98 children with lowtomoderate risk superficial proliferative IH treated in the Department of Dermatology, the Affiliated Hospital of Shandong Second Medical University. According to the treatment regimen, they were divided into the laser group (treated with longpulse 1064 nm Nd:YAG laser alone, n = 48) and the combination group (treated with longpulse 1064 nm Nd:YAG laser plus topical 2% carteolol hydrochloride ophthalmic solution, n = 50). The effective rate, marked effective rate, number of laser treatments, and incidence of adverse reactions were compared between the two groups. The chisquare test or Fisher's exact test was used for comparison of enumeration data between groups. Results: The effective rate and marked effective rate of the combination group were 90.0% and 76.0%, respectively, which were significantly higher than those of the laser group (83.3% and 58.3%, respectively), with statistically significant differences (both P＜0.05). The number of laser treatments in the combination group was (2.63 ± 0.97) times, which was significantly less than that in the laser group ［(4.25 ± 1.07) times］, and the difference was statistically significant (P＜0.01). Additionally, the incidence of adverse reactions in the combination group was 12%, which was significantly lower than that in the laser group (29%), with a statistically significant difference (P＜0.001). Conclusion: Topical 2% carteolol hydrochloride ophthalmic solution can enhance the efficacy of long-pulsed 1064 nm Nd:YAG laser in the treatment of low- to intermediate-risk superficial proliferative IH, reduce the number of laser treatment sessions, and decrease the incidence of adverse reactions.

Key words: infantile hemangioma, beta-blocker, 2% carteolol hydrochloride ophthalmic solution, long pulse 1064 nm Nd:YAG laser